Sanofi and GSK have reported positive preliminary booster data of their Covid-19 vaccine candidate. The companies said that a single booster shot triggered strong immune responses regardless of the primary vaccine received by the individual. The booster was well tolerated across age groups. Sanofi and GSK added that the ongoing Phase III trial, VAT0008, will continue into early next year to collect more data. The results are expected in the first quarter of 2022.
New Zealand Medicines and Medical Devices Safety Authority, Medsafe have provisionally approved Pfizer’s Covid-19 vaccine for children between five to 11 years of age. Eligible individuals from the age group can receive two doses of the paediatric vaccine at an interval of 21 days, Reuters reported, citing a health ministry statement. The Pfizer vaccine is expected to be introduced in the country before the end of January 2022, subject to New Zealand cabinet approval.
Go deeper with GlobalData
GeoVax Labs has started dosing participants with multi-antigenic SARS-CoV-2 investigational vaccine candidate COH04S1 to evaluate its efficacy as a universal booster to current FDA-approved vaccines. The dosing is part of the Phase II portion of its Phase I/II clinical trial evaluating COH04S1. The trial is being conducted at City of Hope research centre in California. COH04S1 is designed to target both the spike (S) and nucleocapsid (N) proteins.
